Figure 4.

AnxA1_Ac2-26 affords arteriolar protection against cerebral inflammation-induced thrombosis in sickle cell transgenic mice (STM). (A) schematic showing the experimental protocol: (i) STM were subjected to vehicle (saline) or LPS (0.4 mg/kg) for 2 h and (ii) treated with vehicle (saline) or compound(s): AnxA1_Ac2-26 (4 mg/kg) with/without pan FPR antagonist Boc2 (0.4 mg/kg) 20 min prior to thrombosis. (iii) A cranial window was performed and (iv) FITC-dextran was injected (10 mg/kg of 5%). (v) Mice were subjected to intravital microscopy and light/dye-induced thrombus formation, with onset and blood flow cessation times recorded for cerebral (B) arterioles and (C) venules. Data are means ± SEM of 5–6 mice/group. ^# p < 0.05 vs. LPS group. ^ p < 0.05, vs. LPS+AnxA1_Ac2-26 group. ns—non-significant vs. corresponding LPS group.